Report of Foreign Issuer (6-k)

Date : 02/04/2019 @ 1:54PM
Source : Edgar (US Regulatory)
Stock : Sanofi (PC) (SNYNF)
Quote : 89.55  -1.35 (-1.49%) @ 5:46PM
Sanofi (PC) share price Chart

Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2019

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-             

 

 

 


In January and February 2019, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

  

Description

Exhibit 99.1    Press release dated February 4, 2019: CHMP recommends approval of Praluent ® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Exhibit 99.2    Press release dated January 30, 2019: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
Exhibit 99.3    Press release dated January 17, 2019: FDA advisory committee votes on Zynquista™ (sotagliflozin) as treatment for adults with type 1 diabetes

 

2


Exhibit Index

 

Exhibit No.

  

Description

Exhibit 99.1    Press release dated February 4, 2019: CHMP recommends approval of Praluent ® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Exhibit 99.2    Press release dated January 30, 2019: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
Exhibit 99.3    Press release dated January 17, 2019: FDA advisory committee votes on Zynquista™ (sotagliflozin) as treatment for adults with type 1 diabetes

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: February 4, 2019       SANOFI
    By  

/s/ Alexandra Roger

      Name: Alexandra Roger
      Title: Head of Securities Law and Capital Markets

 

4

Sanofi (PC) (USOTC:SNYNF)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Sanofi (PC) Charts.

Sanofi (PC) (USOTC:SNYNF)
Intraday Stock Chart

Today : Saturday 16 November 2019

Click Here for more Sanofi (PC) Charts.

Latest SNYNF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191117 04:54:19